OncoCipherPATIENT
Educational & Guideline Reference Notice: Unranked FDA-label and national guideline option categories and recruiting clinical trials for discussion with a licensed oncologist. Protocol drug dosing and autonomous treatment prescriptions are excluded.

← All Supported Cancers

Non-Small Cell Lung Cancer (NSCLC) — Options & Clinical Trial Reference

Molecularly stratified reference covering EGFR, ALK, ROS1, BRAF V600E, KRAS G12C, MET exon 14, RET, HER2, NTRK, PD-L1 expression, and recruiting trials.

Module v5.0.0 · Curated SHA-256: e49a0a4d5ea0051f · Trial Snapshot: 2026-11-10

Key Biomarkers & Decision Factors:
versionstatuspending_status_valuesequivocal_valuesbiomarkers

Unranked Guideline & FDA-Label Option Categories (92 total)

Option / PathwayCategoryPrimary Sources
Anatomic resection and nodal assessment
Review definitive surgery for operable early NSCLC.
Local treatmentnci_nsclc, calgb140503
Definitive stereotactic radiation review
Review SBRT for medically inoperable, node-negative early disease.
Local treatmentnci_nsclc, rtog0236
Perioperative pembrolizumab plus platinum chemotherapy
Neoadjuvant platinum-based treatment followed by surgery and adjuvant immunotherapy in the studied resectable setting.
Systemic therapyperi_pembro, kn671_5y
Perioperative nivolumab plus platinum chemotherapy
Neoadjuvant platinum-based treatment followed by surgery and adjuvant immunotherapy in the studied resectable setting.
Systemic therapyperi_nivo, cm77t, cm77t_ctgov
Perioperative durvalumab plus platinum chemotherapy
Neoadjuvant platinum-based treatment followed by surgery and adjuvant immunotherapy in the studied resectable setting.
Systemic therapyperi_durva, aegean
Adjuvant platinum-based chemotherapy
Review adjuvant platinum after complete resection in the appropriate stage and treatment sequence.
Systemic therapynci_nsclc, lace
Adjuvant osimertinib
EGFR exon 19 deletion or L858R after complete resection; chemotherapy decision remains separate.
Systemic therapytagrisso, adaura, tagrisso_coverage_20261109
Adjuvant alectinib
ALK-positive disease after complete resection meeting the tumor-size or nodal criterion.
Systemic therapyadj_alectinib, alecensa, alina, alecensa_coverage_20261109, alina_ctgov, elevate_2026
Adjuvant pembrolizumab after platinum
Postoperative immunotherapy after complete resection and platinum, without prior neoadjuvant systemic therapy.
Systemic therapyadj_pembro
Adjuvant atezolizumab after platinum
PD-L1-positive resected stage II–IIIA disease after platinum chemotherapy.
Systemic therapyadj_atezo
Concurrent platinum chemoradiation
Multidisciplinary definitive treatment for unresectable stage III NSCLC.
Systemic therapynci_nsclc
Sequential platinum chemoradiation
Multidisciplinary definitive treatment for unresectable stage III NSCLC.
Systemic therapynci_nsclc
Durvalumab after concurrent chemoradiation
Consolidation after concurrent platinum chemoradiation without progression.
Systemic therapyimfinzi, pacific5
Osimertinib after chemoradiation
EGFR exon 19 deletion or L858R disease without progression after definitive platinum chemoradiation.
Systemic therapylaura, laura_updated_2026
Osimertinib
Molecularly selected advanced-disease pathway; use the exact alteration and prior-treatment context.
Systemic therapytagrisso, flaura2_os, tagrisso_coverage_20261109

View all 92 Non-Small Cell Lung Cancer (NSCLC) reference options →

Recruiting Clinical Trials (46 curated)

NCT IDStudy TitlePhase
NCT03175224APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsPHASE2
NCT03191149Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 ChangePHASE2
NCT03851445Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerPHASE2/PHASE3
NCT04410796Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung CancersPHASE2
NCT04486833Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on OsimertinibPHASE1/PHASE2
NCT04613596Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7PHASE2/PHASE3
NCT05099172First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)PHASE1/PHASE2
NCT05144698RAPA-201 Therapy of Solid TumorsPHASE1/PHASE2
NCT05150691A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsPHASE1/PHASE2
NCT05456256A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung AdenocarcinomaPHASE2
NCT05785741A Study of DB-1310 in Advanced/Metastatic Solid TumorsPHASE1/PHASE2
NCT05920356A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)PHASE3

View all 46 Non-Small Cell Lung Cancer (NSCLC) clinical trials →